PTGS2 and myocardial infarction: Moreover, COX-2-selective drugs such as coxibs, rofecoxib, celecoxib, and lumiracoxib NSAIDs, inhibit cyclooxygenase-2 (COX-2), thereby suppressing the biosynthesis of PGI2, and increasing the risk of thrombotic events such as in myocardial infarction and stroke [83,84].